Drugs a ad-ae
| Drug Name | Add To My List | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adalimumab | |||||||||||
HUMIRA
|
|||||||||||
| Adapalene | |||||||||||
DIFFERIN GEL
|
|||||||||||
DIFFERIN CREAM
|
|||||||||||
DIFFERIN LOTION
|
|||||||||||
EPIDUO GEL
|
|||||||||||
DIFFERIN GEL 0.1%
|
|||||||||||
EPIDUO FORTE GEL
|
|||||||||||
| Adefovir | |||||||||||
HEPSERA
|
|||||||||||
| Adenosine | |||||||||||
ADENOCARD
|
|||||||||||
ADENOSCAN
|
|||||||||||
| Ado-trastuzumab | |||||||||||
KADCYLA
|
|||||||||||
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
- New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D
- Peer-Led Education Helps Physicians Save Time With EHRs
- As Immigration Policies Tighten, Physician Shortage Concerns Grow
Sign Up for Free e-Newsletters
Check out what's trending
CME Focus
Blocking TSH-Receptor Antibodies in Autoimmune Thyroid Disease
CME|CE
4.00 Credits
Case 3 - A 19-Year-Old Latina College Student with Prediabetes
CME|CE
1.25 Credits